Cargando…
The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis
BACKGROUND: The role of the pulmonary microbiome in sarcoidosis is unknown. The objectives of this study were the following: (1) examine whether the pulmonary fungal and bacterial microbiota differed in patients with sarcoidosis compared with controls; (2) examine whether there was an association be...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580159/ https://www.ncbi.nlm.nih.gov/pubmed/36258251 http://dx.doi.org/10.1186/s40168-022-01362-4 |
_version_ | 1784812332992430080 |
---|---|
author | Knudsen, Kristel S. Lehmann, Sverre Nielsen, Rune Tangedal, Solveig Paytuvi-Gallart, Andreu Sanseverino, Walter Martinsen, Einar M. H. Hiemstra, Pieter S. Eagan, Tomas M. |
author_facet | Knudsen, Kristel S. Lehmann, Sverre Nielsen, Rune Tangedal, Solveig Paytuvi-Gallart, Andreu Sanseverino, Walter Martinsen, Einar M. H. Hiemstra, Pieter S. Eagan, Tomas M. |
author_sort | Knudsen, Kristel S. |
collection | PubMed |
description | BACKGROUND: The role of the pulmonary microbiome in sarcoidosis is unknown. The objectives of this study were the following: (1) examine whether the pulmonary fungal and bacterial microbiota differed in patients with sarcoidosis compared with controls; (2) examine whether there was an association between the microbiota and levels of the antimicrobial peptides (AMPs) in protected bronchoalveolar lavage (PBAL). METHODS: Thirty-five sarcoidosis patients and 35 healthy controls underwent bronchoscopy and were sampled with oral wash (OW), protected BAL (PBAL), and left protected sterile brushes (LPSB). The fungal ITS1 region and the V3V4 region of the bacterial 16S rRNA gene were sequenced. Bioinformatic analyses were performed with QIIME 2. The AMPs secretory leucocyte protease inhibitor (SLPI) and human beta defensins 1 and 2 (hBD-1 and hBD-2), were measured in PBAL by enzyme-linked immunosorbent assay (ELISA). RESULTS: Aspergillus dominated the PBAL samples in sarcoidosis. Differences in bacterial taxonomy were minor. There was no significant difference in fungal alpha diversity between sarcoidosis and controls, but the bacterial alpha diversity in sarcoidosis was significantly lower in OW (p = 0.047) and PBAL (p = 0.03) compared with controls. The beta diversity for sarcoidosis compared with controls differed for both fungi and bacteria. AMP levels were significantly lower in sarcoidosis compared to controls (SLPI and hBD-1: p < 0.01). No significant correlations were found between alpha diversity and AMPs. CONCLUSIONS: The pulmonary fungal and bacterial microbiota in sarcoidosis differed from in controls. Lower antimicrobial peptides levels were seen in sarcoidosis, indicating an interaction between the microbiota and the innate immune system. Whether this dysbiosis represents a pathogenic mechanism in sarcoidosis needs to be confirmed in experimental studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40168-022-01362-4. |
format | Online Article Text |
id | pubmed-9580159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-95801592022-10-20 The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis Knudsen, Kristel S. Lehmann, Sverre Nielsen, Rune Tangedal, Solveig Paytuvi-Gallart, Andreu Sanseverino, Walter Martinsen, Einar M. H. Hiemstra, Pieter S. Eagan, Tomas M. Microbiome Research BACKGROUND: The role of the pulmonary microbiome in sarcoidosis is unknown. The objectives of this study were the following: (1) examine whether the pulmonary fungal and bacterial microbiota differed in patients with sarcoidosis compared with controls; (2) examine whether there was an association between the microbiota and levels of the antimicrobial peptides (AMPs) in protected bronchoalveolar lavage (PBAL). METHODS: Thirty-five sarcoidosis patients and 35 healthy controls underwent bronchoscopy and were sampled with oral wash (OW), protected BAL (PBAL), and left protected sterile brushes (LPSB). The fungal ITS1 region and the V3V4 region of the bacterial 16S rRNA gene were sequenced. Bioinformatic analyses were performed with QIIME 2. The AMPs secretory leucocyte protease inhibitor (SLPI) and human beta defensins 1 and 2 (hBD-1 and hBD-2), were measured in PBAL by enzyme-linked immunosorbent assay (ELISA). RESULTS: Aspergillus dominated the PBAL samples in sarcoidosis. Differences in bacterial taxonomy were minor. There was no significant difference in fungal alpha diversity between sarcoidosis and controls, but the bacterial alpha diversity in sarcoidosis was significantly lower in OW (p = 0.047) and PBAL (p = 0.03) compared with controls. The beta diversity for sarcoidosis compared with controls differed for both fungi and bacteria. AMP levels were significantly lower in sarcoidosis compared to controls (SLPI and hBD-1: p < 0.01). No significant correlations were found between alpha diversity and AMPs. CONCLUSIONS: The pulmonary fungal and bacterial microbiota in sarcoidosis differed from in controls. Lower antimicrobial peptides levels were seen in sarcoidosis, indicating an interaction between the microbiota and the innate immune system. Whether this dysbiosis represents a pathogenic mechanism in sarcoidosis needs to be confirmed in experimental studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40168-022-01362-4. BioMed Central 2022-10-19 /pmc/articles/PMC9580159/ /pubmed/36258251 http://dx.doi.org/10.1186/s40168-022-01362-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Knudsen, Kristel S. Lehmann, Sverre Nielsen, Rune Tangedal, Solveig Paytuvi-Gallart, Andreu Sanseverino, Walter Martinsen, Einar M. H. Hiemstra, Pieter S. Eagan, Tomas M. The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis |
title | The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis |
title_full | The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis |
title_fullStr | The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis |
title_full_unstemmed | The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis |
title_short | The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis |
title_sort | lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580159/ https://www.ncbi.nlm.nih.gov/pubmed/36258251 http://dx.doi.org/10.1186/s40168-022-01362-4 |
work_keys_str_mv | AT knudsenkristels thelowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis AT lehmannsverre thelowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis AT nielsenrune thelowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis AT tangedalsolveig thelowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis AT paytuvigallartandreu thelowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis AT sanseverinowalter thelowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis AT martinseneinarmh thelowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis AT hiemstrapieters thelowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis AT eagantomasm thelowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis AT knudsenkristels lowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis AT lehmannsverre lowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis AT nielsenrune lowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis AT tangedalsolveig lowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis AT paytuvigallartandreu lowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis AT sanseverinowalter lowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis AT martinseneinarmh lowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis AT hiemstrapieters lowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis AT eagantomasm lowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis |